학술논문
A Phase 1b Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116
Document Type
article
Author
Source
Liver Cancer (2023)
Subject
Language
English
ISSN
1664-5553
Abstract
Background: Treatment with lenvatinib (dosing for patients who weigh ≥60 kg was 12 mg/day; for patients who weigh